AI-Powered Blood Test Set to Revolutionize Early Fetal Genetic Screening

Identifai Genetics, an Israeli company, is making headlines as it prepares to list on the Australian stock exchange (ASX) on October 16, 2026, with an Initial Public Offering (IPO) that raised $10 million. The company aims to change how we screen unborn babies by using its special Windrose™ platform, which combines Artificial Intelligence (AI) with blood samples to check for more than 280 different genetic conditions very early in pregnancy. This is a big step forward compared to current tests that look for far fewer conditions, offering parents much more detailed information sooner than before. Currently, most non-invasive prenatal testing (NIPT) looks for only a few common problems, like Down syndrome, but Identifai's technology, developed from research at Tel Aviv University, can scan an unborn baby's entire genetic makeup from just a single maternal blood sample taken from nine weeks of pregnancy. This wider scan is especially good for finding 'monogenic disorders', which are caused by a change in just one gene and are often missed by older tests. The company has already shown promising results, with 100% accuracy in detecting conditions in early tests on high-risk pregnancies, meaning fewer families might need riskier invasive procedures like amniocentesis. As Identifai Genetics gets ready for its big debut and plans to launch its Windrose™ platform in the United States, all eyes will be on its upcoming larger clinical validation study involving about 600 patients across different US hospitals. If these trials continue to show strong results, this AI-powered approach could soon become a common part of prenatal care, giving expecting parents more peace of mind and allowing doctors to prepare for or even treat certain conditions much earlier. This move highlights a growing trend in biotechnology where AI is used to make medical tests smarter and safer.